Inogen Inc (INGN) Form 8-K — Aug 6, 2026
Inogen reported second quarter 2026 revenue of $95.1 million, up 3.0% year over year, with the GAAP net loss narrowing to $3.9 million from $4.2 million and adjusted EBITDA of $2.4 million, up 15.2% year over year. Management raised full-year 2026 adjusted EBITDA guidance to approximately $4.0 million, a 48.1% increase from $2.7 million reported in 2025, and set full-year revenue guidance at $355 million to $361 million, roughly 3% growth at the midpoint, while guiding Q3 revenue approximately in line with the prior year. Growth was concentrated internationally, where revenue rose 14.8% to $41.3 million, while U.S. sales fell 2.3% and U.S.
Key figures
- Revenue
- 95084000
- Guidance
- FY2026 revenue $355M-$361M (~3% growth at midpoint); FY2026 adjusted EBITDA raised to ~$4.0M (48.1% increase from $2.7M in 2025); Q3 2026 revenue expected approximately in line with Q3 2025
- Total Debt
- 0
- Revenue Yoy
- 3.0%
- Total Assets
- 285572000
- Cash Position
- 106800000
- Gross margin
- 45.5% vs 44.8% prior year
- Free cash flow q2
- 1027000
- Adjusted ebitda q2
- 2397000
- Adjusted ebitda yoy
- +15.2%
- Us sales change yoy
- -2.3%
- Adjusted gross margin
- 45.6% vs 44.9% prior year
- Us rentals change yoy
- -11.8%
- Operating cash flow q2
- 2946000
- Portable units sold q2
- 53300
- International growth yoy
- +14.8%
- International revenue q2
- 41300000
- Shares repurchased h1 2026
- 1,145,150 shares for $7.5 million
- Net rental patients period end
- 45500
- Constant currency revenue growth q2
- 0.6%
- Stockholder engagement proxy defense costs q2
- 580000
Price after filing
Close on the filing date to close N calendar days later (from $6.92). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.